new glp 1 agonist novo nordisk stops trial of Ozempic in kidneys as interim analysis shows success glp 1 agonist novo nordisk
Description
Allan KC, et al
As Wegovy, it received FDA approval specifically for the treatment of obesity in 2021
Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide only activates GLP-1 receptors
doi: 10.1038/nrendo.2011.183 3 ZinmanBWannerCLachinJMFitchettDBluhmkiEHantelSet al
Its anti-inflammatory mechanisms operate entirely through GLP-1R activation
Association of GLP-1 receptor agonists with risk of intestinal obstruction in patients with type 2 diabetes mellitus: a retrospective cohort study
